Potential treatment for polymorphic light eruption A 2010 phase III, randomized, double blind, placebo controlled, parallel group study was undertaken in Germany, the Netherlands, and Belgium to evaluate the safety and efficacy of subcutaneous implants of melanotan I (16 mg) in patients suffering from polymorphic light eruption (PLE), a condition characterized by a rash following exposure to sunlight
Phentermine is not appropriate for patients with: Coronary heart disease, congestive heart failure, heart rhythm problems, or a history of stroke Uncontrolled high blood pressure Untreated thyroid problems (hyperthyroidism) Pulmonary hypertension Untreated glaucoma Use of an MAO inhibitor (a class of antidepressants) within the last 14 days including rasagiline, tranylcypromine, selegiline, phenelzine, linezolid, and isocarboxazid Can I start phentermine at the highest dose
Treatment with Trametes versicolor polysaccharide (EVP) dramatically reduced serum TC, TG, LDL-C, and atherosclerosis index in a dose-dependent manner in high-fat diet-induced hyperlipidemic mice
A warm, firm response and a subject change are enough
& Panov, A